#United States #New York #Securities Class Action #Faruqi & Faruqi #Ultragenyx

Deadline Approaches for Ultragenyx Investors

In a significant development for investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), the national securities law firm Faruqi & Faruqi, LLP has extended an urgent reminder regarding the deadline for a federal securities class action lawsuit. This deadline is set for April 6, 2026. If you have incurred losses in Ultragenyx securities from August 3, 2023 to December 26, 2025, it is crucial to understand your legal rights and options now.

Background on the Allegations

Faruqi & Faruqi is currently investigating potential claims against the company, which has purportedly made misleading statements and failed to disclose critical information surrounding its clinical studies. The complaint specifically highlights two major issues:

1. Misleading Information on Setrusumab: The firm's executives allegedly provided the impression that they had reliable data regarding the impacts of setrusumab—a treatment for Osteogenesis Imperfecta (OI)—on patients. However, they downplayed significant risks associated with the trial's outcomes. This misrepresentation led investors to have unwarranted optimism about the drug's efficacy, creating a false sense of security.

2. Failure of Phase III Orbit Study: On July 9, 2025, it became evident that Ultragenyx's Phase III Orbit study had not achieved statistical significance in its second interim analysis. Following this announcement, Ultragenyx's stock experienced a drastic drop of over 25%. Later, on December 29, 2025, the company confirmed that both its Phase III Orbit and Cosmic studies failed to meet their primary endpoints, causing another substantial drop of approximately 42% in stock value.

These events clearly indicate a serious discrepancy between what was communicated to investors and the actual findings of the clinical studies. Both of these events underscore the need for vigilant and proactive action among impacted investors.

The Role of Lead Plaintiff

In class action lawsuits, a lead plaintiff is often appointed to direct the litigation on behalf of all affected investors. This individual can significantly impact the case's direction and recoveries made. If you wish to seek this role or want more details on your options, acting promptly is imperative.

Faruqi & Faruqi's partner, James (Josh) Wilson, has encouraged investors who suffered losses to reach out directly. He can be contacted at 877-247-4292 or 212-983-9330 (Ext. 1310). Furthermore, those with knowledge regarding Ultragenyx’s activities are invited to communicate with the firm as potential witnesses. This includes former employees and shareholders who may provide crucial insights into the company's actions leading up to the class action.

Important Steps to Take

If you are an investor who experienced losses during the class period, consider the following steps:

• - Contact Legal Expertise: Reaching out to Faruqi & Faruqi can help you understand your legal rights and options.
• - Gather Documentation: Keep records of your transactions related to Ultragenyx, as this documentation may be essential in proving your case.
• - Stay Informed: Follow updates from Faruqi & Faruqi or relevant news sources to stay abreast of developments related to Ultragenyx and the ongoing litigation.

Class actions serve to protect investors from misleading behavior by companies and provide a mechanism for obtaining compensation for losses incurred. It’s critical not to overlook this upcoming deadline, as it could impact your ability to seek redress for your investments. Act now to understand your position and explore your options, ensuring you don’t miss the opportunity to participate in the proceedings against Ultragenyx Pharmaceutical.

For more information, visit Faruqi & Faruqi's website.